Filing Flows › Metagenomi Therapeutics (MGX) › Q4 2025 › vs Q4 2024
Metagenomi Therapeutics (MGX) Q4 2025 vs Q4 2024 (year over year)
Metagenomi Therapeutics's revenue fell $5.7M (-59%) from $9.6M in Q4 2024 to $3.9M in Q4 2025.
Metagenomi Therapeutics, Q4 2025: revenue $3.9M (-59% year over year), operating margin -623.0%, net loss $22.5M, operating cash flow −$23.5M. The chart draws each line against Q4 2024, the increases inside each band.
Every line
| Line | Q4 2025 | Q4 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $3.9M | $9.6M | −$5.7M | -59% |
| Other income, net | $1.9M | −$4.0M | $5.9M | — |
| Net loss | $22.5M | $23.4M | −$870K | -4% |
| Costs & expenses | $28.3M | $34.2M | −$5.9M | -17% |
| Operating costs | $28.3M | $30.2M | −$2.0M | -6% |
| Income tax | $34K | −$1.2M | $1.2M | — |
| Research & development | $21.5M | $23.2M | −$1.7M | -7% |
| General & admin | $6.8M | $7.1M | −$296K | -4% |
| Operating cash sources | $27.5M | $31.1M | −$3.6M | -12% |
| Depreciation | $1.3M | $1.5M | −$161K | -11% |
| Share-based compensation | $2.7M | $3.4M | −$718K | -21% |
| Cash used in operations | $23.5M | $26.3M | −$2.7M | -10% |
| Net loss absorbed | $22.5M | $23.4M | −$870K | -4% |
| Working capital & other | $5.0M | $7.8M | −$2.7M | -35% |
Questions
How much did Metagenomi Therapeutics's revenue grow year over year in Q4 2025?
Metagenomi Therapeutics's revenue fell $5.7M (-59%) from $9.6M in Q4 2024 to $3.9M in Q4 2025.